Digital symptom tracking for kidney cancer treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic kidney cancer with a clear-cell component
- You have not had any prior systemic treatment for your kidney cancer
- Your doctor has decided to treat you with cabozantinib and nivolumab as your first therapy
- If you could become pregnant, you must use effective contraception during and 5 months after treatment
- You are able to use a smartphone, tablet, or computer to report your symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This trial studies how well cabozantinib works for advanced kidney cancer in people who are already receiving hemodialysis. It aims to see whether the treatment is effective and safe for this specific kidney function group.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.